Cargando…

CDK9 is up-regulated and associated with prognosis in patients with papillary thyroid carcinoma

Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy but shows excellent prognosis. We investigated the clinical significance of cyclin-dependent kinase 9 (CDK9) in patients with PTC. This prospective observational study included 192 patients with PTC, who visited our hosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Tao, Liu, De-Feng, Peng, Shi-Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812708/
https://www.ncbi.nlm.nih.gov/pubmed/35119000
http://dx.doi.org/10.1097/MD.0000000000028309
_version_ 1784644712379973632
author Guo, Tao
Liu, De-Feng
Peng, Shi-Hao
author_facet Guo, Tao
Liu, De-Feng
Peng, Shi-Hao
author_sort Guo, Tao
collection PubMed
description Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy but shows excellent prognosis. We investigated the clinical significance of cyclin-dependent kinase 9 (CDK9) in patients with PTC. This prospective observational study included 192 patients with PTC, who visited our hospital between August 2018 and February 2020. We obtained 93 tissue samples from patients with benign thyroid disease during the same period as controls. Immunohistochemical evaluation and reverse transcription-quantitative polymerase chain reaction assay were performed to evaluate CDK9 expression. Patients’ demographic and clinical characteristics were analyzed. Delphian lymph node (DLN) metastasis in patients with PTC was associated with clinicopathological characteristics. CDK9 expression was up-regulated in patients with PTC, and those with DLN metastasis showed higher CDK9 expression. We also observed that tumor size, capsule invasion, tumor-node-metastasis classification (TNM) stage, and multifocality were the risk factors for DLN metastasis in patients with PTC. Additionally, CDK9 expression was strongly associated with tumor size, capsule invasion, TNM stage, and multifocality and weakly associated with the number of metastatic DLN. CDK9 is up-regulated in patients with PTC and associated with prognosis in these patients.
format Online
Article
Text
id pubmed-8812708
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-88127082022-02-05 CDK9 is up-regulated and associated with prognosis in patients with papillary thyroid carcinoma Guo, Tao Liu, De-Feng Peng, Shi-Hao Medicine (Baltimore) 3600 Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy but shows excellent prognosis. We investigated the clinical significance of cyclin-dependent kinase 9 (CDK9) in patients with PTC. This prospective observational study included 192 patients with PTC, who visited our hospital between August 2018 and February 2020. We obtained 93 tissue samples from patients with benign thyroid disease during the same period as controls. Immunohistochemical evaluation and reverse transcription-quantitative polymerase chain reaction assay were performed to evaluate CDK9 expression. Patients’ demographic and clinical characteristics were analyzed. Delphian lymph node (DLN) metastasis in patients with PTC was associated with clinicopathological characteristics. CDK9 expression was up-regulated in patients with PTC, and those with DLN metastasis showed higher CDK9 expression. We also observed that tumor size, capsule invasion, tumor-node-metastasis classification (TNM) stage, and multifocality were the risk factors for DLN metastasis in patients with PTC. Additionally, CDK9 expression was strongly associated with tumor size, capsule invasion, TNM stage, and multifocality and weakly associated with the number of metastatic DLN. CDK9 is up-regulated in patients with PTC and associated with prognosis in these patients. Lippincott Williams & Wilkins 2022-02-04 /pmc/articles/PMC8812708/ /pubmed/35119000 http://dx.doi.org/10.1097/MD.0000000000028309 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle 3600
Guo, Tao
Liu, De-Feng
Peng, Shi-Hao
CDK9 is up-regulated and associated with prognosis in patients with papillary thyroid carcinoma
title CDK9 is up-regulated and associated with prognosis in patients with papillary thyroid carcinoma
title_full CDK9 is up-regulated and associated with prognosis in patients with papillary thyroid carcinoma
title_fullStr CDK9 is up-regulated and associated with prognosis in patients with papillary thyroid carcinoma
title_full_unstemmed CDK9 is up-regulated and associated with prognosis in patients with papillary thyroid carcinoma
title_short CDK9 is up-regulated and associated with prognosis in patients with papillary thyroid carcinoma
title_sort cdk9 is up-regulated and associated with prognosis in patients with papillary thyroid carcinoma
topic 3600
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812708/
https://www.ncbi.nlm.nih.gov/pubmed/35119000
http://dx.doi.org/10.1097/MD.0000000000028309
work_keys_str_mv AT guotao cdk9isupregulatedandassociatedwithprognosisinpatientswithpapillarythyroidcarcinoma
AT liudefeng cdk9isupregulatedandassociatedwithprognosisinpatientswithpapillarythyroidcarcinoma
AT pengshihao cdk9isupregulatedandassociatedwithprognosisinpatientswithpapillarythyroidcarcinoma